DOI: https://doi.org/10.36347/sjmcr.2025.v13i05.009

Pages: 814-819

Methicillin-resistant Staphylococcus aureus (MRSA) is well recognized as a major cause of healthcare-associated infections, but more concerningly, it is now emerging in the community, posing a growing threat to public health. Glycopeptides, particularly vancomycin, have traditionally been the cornerstone of MRSA treatment. However, their overuse has led to the emergence of vancomycin-intermediate and vancomycin-resistant S. aureus (VISA and VRSA, respectively). Although the underlying mechanisms of vancomycin resistance are not yet fully understood, it is believed that modifications in the bacterial cell wall, the site of action of glycopeptides, are crucial. Recent evidence also suggests that genetic material transfer between bacteria may contribute to the development of VRSA. Risk factors for VRSA development include advanced age, lower limb venous insufficiency, chronic ulcers, diabetes, and end-stage renal failure requiring hemodialysis. The spread of MRSA from hospital to community settings, along with the emergence of VISA and VRSA, has become a major concern among clinicians and microbiologists. The limited therapeutic options for these infections highlight the urgent need for new classes of antimicrobial agents. The number of VISA and VRSA infections is likely underestimated due to the limitations of both automated and non-automated detection methods. For clinical and public health reasons, it is essential that microbiology laboratories adequately test for vancomycin resistance in S. aureus. In this article, we report the first case of vancomycin-resistant S. aureus isolated at the CHU Mohammed VI in Marrakech in a patient hospitalized in the infectious diseases department for the management of multifocal tuberculosis complicated by acute renal failure at the hemodialysis stage. The patient responded well to treatment with linezolid and gentamicin, leading to complete resolution of symptoms.